Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-life Versus Extended Half-life Products and Those Switching from Standard Half-life to Extended Half-life Products.
| Author | |
|---|---|
| Abstract |
:
Hemophilia B requires replacement therapy with factor IX (FIX) coagulation products to treat and prevent bleeding episodes. A recently introduced extended half-life (EHL) recombinant FIX replacement product provided the opportunity to compare the amount of dispensed factor and expenditures for EHL treatment compared with a standard half-life (SHL) product. |
| Year of Publication |
:
2018
|
| Journal |
:
Journal of managed care & specialty pharmacy
|
| Number of Pages |
:
1-10
|
| Date Published |
:
2018
|
| ISSN Number |
:
2376-0540
|
| URL |
:
https://dx.doi.org/10.18553/jmcp.2018.17212
|
| DOI |
:
10.18553/jmcp.2018.17212
|
| Short Title |
:
J Manag Care Spec Pharm
|
| Download citation |
